Abstract:An 8-year-old girl with a renal transplant was admitted for myalgia and muscle weakness in both legs over the previous 2 weeks. She also had fever and intermittent epigastric pain. Based on these clinical manifestations, and laboratory and histopathological findings, the diagnosis was coincidence of late-onset cytomegalovirus (CMV)-induced myositis and gastritis in an immunocompromised child with a renal transplant. After administration of intravenous ganciclovir for 3 weeks, her symptoms resolved, with normal… Show more
“…Overall, details on hCMV‐specific anti‐viral therapy were reported in 139/311 (44.7%) cases. According to the information collected, 112 patients were administered ganciclovir monotherapy, 27,83 six valganciclovir monotherapy, 25,29,31,50 and 18 a sequential combination of both drugs 23,24,30,36,41,44,45,51,59,60,62,63,66,74 . Three KTRs did not receive anti‐viral therapy 35,68 .…”
Section: Resultsmentioning
confidence: 99%
“…According to the information collected, 112 patients were administered ganciclovir monotherapy, 27,83 six valganciclovir monotherapy, 25,29,31,50 and 18 a sequential combination of both drugs. 23,24,30,36,41,44,45,51,59,60,62,63,66,74 Three KTRs did not receive anti-viral therapy. 35,68 The duration of ganciclovir and valganciclovir administration ranged from 14 to 35 days and from 21 to 30 days, respectively.…”
Section: Hcmv-gid Treatment and Outcomesmentioning
BackgroundHuman‐cytomegalovirus (hCMV) infection involving the gastrointestinal tract represents a leading cause of morbidity and mortality among kidney transplant (KT) recipients (KTRs). Signs and symptoms of the disease are extremely variable. Prompt anti‐viral therapy administration and immunosuppression modification are key factors for optimizing management. However, complex work‐up strategies are generally required to confirm the preliminary diagnosis. Unfortunately, solid evidence and guidelines on this specific topic are not available.We consequently aimed to summarize current knowledge on post‐KT hCMV‐related gastrointestinal disease (hCMV‐GID).MethodsWe conducted a systematic review (PROSPERO ID: CRD42023399363) about hCMV‐GID in KTRs.ResultsOur systematic review includes 52 case‐reports and ten case‐series, published between 1985 and 2022, collectively reporting 311 cases. The most frequently reported signs and symptoms of hCMV‐GID were abdominal pain, diarrhea, epigastric pain, vomiting, fever, and GI bleeding. Esophagogastroduodenoscopy and colonoscopy were the primary diagnostic techniques. In most cases, the preliminary diagnosis was confirmed by histology. Information on anti‐viral prophylaxis were extremely limited as much as data on induction or maintenance immunosuppression. Treatment included ganciclovir and/or valganciclovir administration. Immunosuppression modification mainly consisted of mycophenolate mofetil or calcineurin inhibitor minimization and withdrawal. In total, 21 deaths were recorded. Renal allograft‐related outcomes were described for 26 patients only. Specifically, reported events were acute kidney injury (n = 17), transplant failure (n = 5), allograft rejection (n = 4), and irreversible allograft dysfunction (n = 3).ConclusionsThe development of local and national registries is strongly recommended to improve our understanding of hCMV‐GID. Future clinical guidelines should consider the implementation of dedicated diagnostic and treatment strategies.
“…Overall, details on hCMV‐specific anti‐viral therapy were reported in 139/311 (44.7%) cases. According to the information collected, 112 patients were administered ganciclovir monotherapy, 27,83 six valganciclovir monotherapy, 25,29,31,50 and 18 a sequential combination of both drugs 23,24,30,36,41,44,45,51,59,60,62,63,66,74 . Three KTRs did not receive anti‐viral therapy 35,68 .…”
Section: Resultsmentioning
confidence: 99%
“…According to the information collected, 112 patients were administered ganciclovir monotherapy, 27,83 six valganciclovir monotherapy, 25,29,31,50 and 18 a sequential combination of both drugs. 23,24,30,36,41,44,45,51,59,60,62,63,66,74 Three KTRs did not receive anti-viral therapy. 35,68 The duration of ganciclovir and valganciclovir administration ranged from 14 to 35 days and from 21 to 30 days, respectively.…”
Section: Hcmv-gid Treatment and Outcomesmentioning
BackgroundHuman‐cytomegalovirus (hCMV) infection involving the gastrointestinal tract represents a leading cause of morbidity and mortality among kidney transplant (KT) recipients (KTRs). Signs and symptoms of the disease are extremely variable. Prompt anti‐viral therapy administration and immunosuppression modification are key factors for optimizing management. However, complex work‐up strategies are generally required to confirm the preliminary diagnosis. Unfortunately, solid evidence and guidelines on this specific topic are not available.We consequently aimed to summarize current knowledge on post‐KT hCMV‐related gastrointestinal disease (hCMV‐GID).MethodsWe conducted a systematic review (PROSPERO ID: CRD42023399363) about hCMV‐GID in KTRs.ResultsOur systematic review includes 52 case‐reports and ten case‐series, published between 1985 and 2022, collectively reporting 311 cases. The most frequently reported signs and symptoms of hCMV‐GID were abdominal pain, diarrhea, epigastric pain, vomiting, fever, and GI bleeding. Esophagogastroduodenoscopy and colonoscopy were the primary diagnostic techniques. In most cases, the preliminary diagnosis was confirmed by histology. Information on anti‐viral prophylaxis were extremely limited as much as data on induction or maintenance immunosuppression. Treatment included ganciclovir and/or valganciclovir administration. Immunosuppression modification mainly consisted of mycophenolate mofetil or calcineurin inhibitor minimization and withdrawal. In total, 21 deaths were recorded. Renal allograft‐related outcomes were described for 26 patients only. Specifically, reported events were acute kidney injury (n = 17), transplant failure (n = 5), allograft rejection (n = 4), and irreversible allograft dysfunction (n = 3).ConclusionsThe development of local and national registries is strongly recommended to improve our understanding of hCMV‐GID. Future clinical guidelines should consider the implementation of dedicated diagnostic and treatment strategies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.